Patents
& Pipeline
IGC Pharma holds a diverse portfolio of granted and pending patents focused on innovative small molecules and pharmaceutical compositions.
These intellectual properties aim to address unmet medical needs in Alzheimer’s Disease, central nervous system disorders, epilepsy, cancer, eating disorders, and more
Safe, well-tolerated and may reduce agitation and
caregiver distress in Alzheimer’s disease.
Pipeline
While IGC-AD1 is the furthest in the clinical trials pipeline, IGC Pharma is actively building a portfolio of small molecules originated from synthetic, semisynthetic, and natural origin, that can address multiple areas of unmet medical needs.
IGC-AD1
TGR-63
1C
M3
LMP
IGC–AD1
Pre Clinical
Phase 1
Phase 2
Target:
Neuroinflammation, Aβ Plaques, Neurofibrillary Tangle
Is an oral investigational therapy combining two natural source actives. Intended to help control Alzheimer’s-related agitation by modulating neuroinflammation and reducing oxidative stress.
- Modulation of neuroinflammation and reduction of oxidative stress.
- Supporting celular metabolic homeostasis and age-related preservation of central nervous system (CNS) cells.
- Modulation of neuronal metabolism and neurotransmission.
- Demonstrated safety and tolerability.
- Indicated reduction in neuropsychiatric symptoms in Alzheimer’s patients.
- Efficacy on agitation in Alzheimer’s.
- Efficacy on improvement in cognition due to Alzheimer’s.
Intellectual Property and Patents
IGC Pharma has a portfolio of approved and pending patents on small molecules and innovative pharmaceuticals with the potential to treat Alzheimer’s Disease and other conditions.
